Athenex Inc

Nuvation Bio

Longboard Pharmaceuticals

Syndax Pharmaceuticals

Kura Oncology, Inc.

Incyte Corporation

HOOKIPA Pharma

Celcuity Inc

HUTCHMED China

305 PubMed publications found for Athenex

Pregnancy-associated progression with spontaneous postpartum regression in metastatic alveolar soft part sarcoma.

Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.

A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors.

UpSMART: five years of digital innovation in cancer clinical research-achievements, challenges, and recommendations.

First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation.

306 PubMed publications found for Athenex

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

307 PubMed publications found for Athenex

SW convergence: 50/100 (Neutral), 0 bullish / 0 bearish signals

<article class="bts-verified-summary" data-ticker="ATNX">
<p>Athenex Inc (ATNX) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>No Form 4 insider filings for ATNX were recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22ATNX%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR

Athenex Inc (ATNX) — BioTechSigns Verified Summary

Athenex Inc (ATNX) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

No Form 4 insider filings for ATNX were recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22ATNX%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11